HeartBeam Inc. is a medical technology company focused on transforming cardiac disease detection and monitoring through innovative electrocardiogram solutions. The company has developed the first cable-free device capable of collecting electrocardiogram signals in three dimensions from non-coplanar directions and synthesizing them into clinical-grade 12-lead electrocardiograms. HeartBeam's flagship product, HeartBeam AIMIGo, is a credit card-sized portable device coupled with a smartphone application and cloud-based diagnostic software system that enables remote evaluation of cardiac symptoms outside traditional healthcare settings. The company's proprietary Vector Electrocardiography platform creates three-dimensional vector images of cardiac electrical activity, allowing physicians to identify cardiac health trends and acute conditions and direct patients to appropriate care. HeartBeam received FDA clearance for its 3D electrocardiogram technology for arrhythmia assessment in December 2024 and for its 12-lead electrocardiogram synthesis software in December 2025. The platform is designed for use in both clinical and at-home settings, with readings reviewed by on-demand board-certified cardiologists. Founded in 2015 and headquartered in Santa Clara, California, HeartBeam holds over 20 issued patents related to its technology and is advancing applications in heart attack detection and artificial intelligence-enabled cardiac screening.